I was enrolled as Graduate Partnerships Program at NIH, USA and awarded pre-doctoral fellow by Vaccine Research Center at NIAID to conduct my Ph.D. dissertation research from 2011 to 2012. I continued my research work at National Cancer Institute at NIH, the USA as a postdoctoral fellow after obtaining my Ph.D. degree in immunology from Chinese Center for Disease Control and Prevention (China CDC), Beijing, China in July 2012. During my Ph.D. study, my research efforts focused on dissecting the adaptive immune responses mainly humoral immune responses mounted during natural HIV-1 infection to inform valuable information for rational preventive and therapeutic strategy development against AIDS/HIV. Currently, my postdoctoral research efforts extended to the novel vaccine development against HIV/SIV and testing them in the non-human primate model and further identified the immune protection mechanism of candidate vaccines against SIV/HIV. Additionally, I am actively exploring the novel combined therapy strategies including gene therapy and immunization approaches to eradicate/remiss the latent reservoir for HIV/SIV and novel immunotherapy strategies for cancer. I serve as editorial board member for the Academia Journal of Scientific Research, the BAOJ HIV, the ARC Journal of AIDS, the Journals of Scientific & Academic Publishing, the Journal of Child, Adult Vaccines and Immunology, the Journal of Insights in Clinical and Cellular Immunology and reviewers for multiple international peer-reviewed journals and book chapter. I am also the member of American Society for Microbiology (ASM) and the American Association for the Advancement of Science (AAAS).
Virology and Immunology mainly including the following directions:
1) Infection and immunity for medical viruses including HIV/AIDS;
2) Rational Development of Preventive and Therapeutic Strategy against retroviruses including SIV/HIV;
3) Dissection of Immune Protection mechanism of candidate vaccines against SIV/HIV;
4) Immunization strategy optimization and novel adjuvant discovery;
5) Novel immunotherapy approach for cancer.
Steve Porcella, University NIH, NIAID, USA
Dr. Steve Porcella received his Ph.D. from the University of Montana while studying Neisseria gonorrhoeae and N. meningitidis. A postdoctoral/assistant instructor position followed at the University of Texas Southwestern Medical Center in Dallas, where he also managed a DNA-sequencing core facility and performed research on Treponema pallidum (syphilis) and Borrelia burgdorferi (Lyme disease). In 1996, he took a position in the Laboratory of Microbial Structure and Function at Rocky Mountain Laboratories (RML), National Institute of Allergy and Infectious Diseases (NIAID), where his work focused on B. burgdorferi and T. pallidum. In 1997, Dr. Porcella transitioned into Dr. Tom Schwan’s Laboratory where his research focused on relapsing feverBorrelia. In 2001, under Dr. James Musser, who is now at Houston Methodist, Steve was appointed staff scientist and facility head within the Laboratory of Human Bacterial Pathogenesis, where his research shifted to include the study of Streptococcus pyogenes. In 2005, Dr. Porcella became head of the newly formed Research Technologies Section (RTS), within the Research Technologies Branch, headed by Branch Chief Dr. Robert Hohman. The RML RTS, which includes the Electron Microscopy Unit, the Flow Cytometry Unit, Visual Medical Arts Unit and the Genomics Unit, provides state-of-the-art technologies and expertise to approximately 120 intramural NIAID laboratories on the Bethesda main campus and at RML. Dr. Porcella’s expertise lies in genomics, microarrays, human and pathogen genotyping, sequencing, and bioinformatics.
Genomics, NGS, RNA-SEQ, Host-pathogen.
Chunhua Song, University: Pennsylvania, USA
Dr Chunhua Songgraduated from Medical School in China and obtained his Ph.D. on Molecular and Cellular Biology in Kobe University School of Medicine, Japan. He also worked postdoctoral fellow at Department of Pharmacology, Research Scientist at Department of Paediatrics, University of Wisconsin-Madison, USA. Since 2010, Dr Song moved to Penn State University College of Medicine as Assistant Professor and now and now as Associate professor at Department of Paediatrics.
The goal of Dr Song’s research is to understand the epigenetic and transcriptional regulation of cancer, develop novel therapy for cancer and also hepatitis viral infections in human. His contributions to science include transcriptional and epigenetic regulation in Leukemia and CK2 inhibitor for leukemia therapy, identification of novel poly A polymerase regulated by phospholipid (Star-PAP), discovery of a novel phospholipase C (PLCepsilon) regulated by Ras, identification of biomarkers in cancer, anti-tumour effect of potential new drugs. Dr Song also have contributions on ion channels, hepatitis infection, etc..
Dr. Mark Manak heads up the research activities of the Department of Laboratory Diagnostics and Monitoring focusing on evaluation of diagnostic assays and their applications in screening for HIV and related infectious diseases and monitoring efficacy of intervention programs. Prior to Joining MHRP, Dr. Manak was the Chief Scientist of SeraCare Life Sciences Inc. where he led the development of seroconversion and performance panels widely used by the in vitro diagnostics community for development, evaluation, and validation of in vitro diagnostic assays used in screening and monitoring of infectious diseases. Dr. Manak received his Ph.D. in Biochemistry and Biophysics, from the University of Connecticut, and did Postdoctoral studies at Johns Hopkins in molecular events in control of viral infections.
Mark Manak’s research interests focus on evaluation of diagnostic assays and their applications in screening for HIV and related infectious diseases. These studies help guide the selection and validation of most effective test algorithm for detection of HIV infection and evaluation of epidemiological, vaccine and therapeutic initiatives.
Michael Themis, Brunel University, UK
Teaching at Brunel University and Imperial College London, at BSc and MSc levels. Research (h-index 30). Experience includes gene therapy of genetic diseases predominantly in a fetal and neonatal context and to stem cells using a virus-based approach. Development of models for testing virus vectors for gene therapy genotoxicity in vivo and in vitro. Use of several animal models of disease including Cystic fibrosis, Duchenne muscular dystrophy and familial hypercholesterolaemia and Friedreich ataxia. Investigation of the effects of lentivirus integration on DNA damage and instability using RV, LV and AAV vectors. Currently funded by Ataxia UK and MRC NC3Rs via Innovate UK GSK/Novartis. Winner of the InMutaGene Challenge.
Gene Therapy, genotoxicity, cancer, stem cells, DNA damage repair.
Wei Zhu, Tongji University, China
Proficient in tissue sections, immunohistochemistry, immunofluorescence, radioimmunoassay, ELISA, flow cytometry, extraction (RNA, DNA, Protein, Nucleoprotein) of tissues and cells, PCR, Real time PCR, culture of animal cells including neuron stem cells, western blot, EMSA, Pull down, immunoprecipitation, molecular clone and expression, cell transfection, screening of monoclonal cell, construction of stable cell line, DNA methylation sequencing and analysis, isolation and culture of bacteria, operation of animal model (mouse, rat) on feeding, gavage administration, nipple perfusion, serum and tissues collections, diagnosis for diseases of livestock and poultry, et al.
Guoqiang Zhu, Yangzhou University, China
Key National Laboratory of Animal Virology , Changchun University of Agriculture and Animal Science (now the College of Veterinary Medicine, Jilin University), Changchun.
Veterinary Microbiology, pathogen and host cell.
Guigao Lin, National Center for Clinical Laboratories, China
Clinical virology diagnostics; quality control of clinical molecular genetics; CRISPR/Cas9 based genomic editing and its application in molecular therapy, diagnostics, and quality control of genetic testing; virology Immunology.
Sameeh Salem Ghazal, Affaire University, Saudi Arabia
Since graduation from medical college, 32 years back (1982), I worked as a medical doctor.
Consultant epidemiology infection control - Consultant Infectious diseases.
Tao Zuo, Therapeutics The Chinese University, China
Postdoctoral research fellow, Department of Medicine and Therapeutics, The.
Gut microbiota, inflammatory bowel disease, food nutrition and therapy
Claudia Grasso, University of Catania, Italy
Ciotti Marco, Rome Tor Vergata University, Italy
Human papillomavirus, viral hepatitis, human polyomaviruses, molecular virological diagnosis.
Francesca Caccuri, University of Brescia, Italy
1. Dr. Francesca Caccuri is a PhD in Virology and Microbiology. She is currently assistant Professor at the University of Brescia (Italy). Dr. Caccuri has published several papers on the HIV-1 matrix protein p17 and has a specific experience in studying p17 biological activity in different cells. She has been involved in the study of the chemokine-like properties of p17 pointing to the identification of cellular receptors. She has been particularly interested in the study of p17-mediated angiogenesis and lymphangiogenesis both in vitro and in vivo. She has been directly involved in studying the activity of p17 and its variants on B-cell proliferation, survival and clonogenicity. She took part in the isolation and description of p17 and its variants in plasma, PBMCs and tumor biopsies. Moreover, Dr. Caccuri has a large experience in cell biology (with particular experience in the development of primary human endothelial cells), molecular biology, genetic engineering and immunology (vaccine development). She has been working at the Center for Cancer Research of the National Cancer Institute (NCI/NIH), Bethesda, MD, where she collaborated in studies aimed to down-modulate regulators of immune response in HIV-1-infected individuals, using the macaque model of SIV infection. During her fellowship at the Microbiology and Virology section of the University of Brescia, Italy, she participate to the development of a therapeutic vaccine against AIDS that was successfully tested in a phase I clinical trial in Italy. At the Virology Institute of the University of Zurich, Switzerland, she acquired experience in developing, manipulating and using different viral vectors for gene therapy. Moreover in the Angiogenesis and Vascular Biology laboratory at the Manchester Metropolitan University, UK, she maturated a strong experience in studying the mechanisms of aberrant angiogenesis in brain endothelial cells operated by viral proteins.
1. Vaccine development; Immunology; Gene therapy; Cancer and its biological basis; Anticancer therapy; Angiogenesis and lymphangiogenesis Lymphoma; HIV/AIDS; AIDS related diseases; Intracellular signaling pathways.
Olivier Reynard, CIRI University, France
Dr. Olivier Reynard is an expert virologist, he hold a doctorate from EPHE University (La Sorbonne, Paris, France). He has over fifteen years’ experience of virological research mainly in the field of academic research on hemorrhagic fever viruses but also as a consultant in major pharmaceutical industry and biotech companies. His expertise includes vaccine design and testing, virus isolation and manipulation in high containment facility (BSL4), cell and viral molecular biology, biochemistry study of proteins and design of antiviral drug screening assays. He is the author/co-author of several scientific peer reviewed articles and owned several patents. He acts as an associate professor at Lyon Catholic University, where he teaches biosafety and virology in bachelor and M.Sc courses.
Ebola virus and other haemorrhagic fever viruses
Karimeldin Mohamed Ali Salih, University of Bahri,Khartoum, Saudi Arabia
Edivaldo Costa Sousa Júnior, Evandro Chagas Institute, Brazil
He holds a degree in biomedicine from the Federal University of Pará (UFPA). Master in Genetics and Molecular Biology with Emphasis in Bioinformatics (UFPA). Currently works at the Evandro Chagas Institute, in the Virology Section, possessing knowledge in the area of General Virology, Arbovirology and Structural and Functional Genomics.
General Virology, Animal Virology, Arbovirology, Structural Genomics, Functional Genomics, Evolution and Bioinformatics.
Ganesh Selvaraj Duraisamy, Veterinary Research University, Czech Republic
Development and testing of novel antivirals active against TBEV, Zika, WNV, rabies
Angel S. Galabov, The Stephan Angeloff Institute, Bulgaria
Dr. Angel Simeonov Galabov is a professor of virology in The Stephan Angeloff Institute of Microbiology, Sofia, Bulgaria. He completed his Ph.D. at Bulgarian Academy of Sciences and M.D at Higher Medical School, Sofia, Bulgaria. He held many positions in his carrier. He is Regular Member of the Bulgarian Academy of Sciences and is a member of several other Scientific Organizations. He has 40 patent inventions and 271scientific refereed publications, including twomonograph and several chapters in books. He received award and honors; Awarded twice by the Bulgarian Academy of Sciences by the Sign of Honor “Marin Drinov” in 2009and in 201
antivirals (viral replication inhibitors, biological response modifiers), enteroviruses, influenza viruses, adenoviruses et al., oncolytic viruses, human papilloma viruses, Balkan endemic nephropathy, antiviral microbicides,molecular genetic base (mtDNA, Y-chromozome DNA) of the origin of Bulgarians
Rafał Pawliczak, Medical University, Poland
asthma, rhinitis, urticaria, molecular mechanism of allergy
Abraham Yaniv, Tel Aviv University, Israel
Molecular and Clinical Virology as I am teaching Virology
Retroviruses, Signal transduction in cancer cells, HPVs
Signal transduction in cancer cells
Signal transduction in cancer cells
Retroviruses in human cancer
Dina Nadeem Abd-Elshafy, water pollution research University, Egypt
B. Sc. Microbiology- Chemistry department, Faculty of Science Ain Shams University (very good, honor degree) in 1999.
Hepatitis viruses research (specially A and C), antiviral research, viral water pollution research.